Figure 4.
Changes in β2μ levels were observed with treatment with MEDI-507 for 6 months in a MET-1 ATL–bearing NOD/SCID mouse. Human β2μ serum levels were used as a surrogate tumor marker in this human xenograft MET-1 ATL model.
Changes in β2μ levels were observed with treatment with MEDI-507 for 6 months in a MET-1 ATL–bearing NOD/SCID mouse. Human β2μ serum levels were used as a surrogate tumor marker in this human xenograft MET-1 ATL model.
